GHP September 2016

ghp September 2016 | 31 Currently MRgFUS has already been adopted and used by world recognised physicians in more than 120 leading medical facilities around the world. The treatment offers access to new and untapped seg- ments of patients and holds the promise for a range of neurosurgical procedures. Exablate Neuro already holds a CE mark for essential tremor, tremor dominant Parkinson’s disease and neuropathic pain, but as the treatment becomes more widespread it presents an opportunity for physicians to research new appli- cations and provide patients with new non-invasive treatment options. Name: Rick Schallhorn Web Address: